[ET Net News Agency, 12 February 2026] Morgan Stanley raised the target price for WuXi
Bio (02269) to HKD50 from HKD45 and maintained the "overweight" rating.
The research house said it raises 2026-30 earnings estimates by 4-10% on accelerating
revenue growth and margin expansion. (rc)